患者报告的病结果的使用和影响
Kristl Vonck1, Arnaud Biraben2, Magdalena Bosak3
1Department of Neurology, 4Brain, Ghent University Hospital, Gent, Belgium.
Brain and behavior
|November 24, 2023
概括
患者报告结果 (PRO) 在欧洲越来越多地用于管理,尽管常规收集方式各不相同. 协调PRO测量对于患者相关性和医疗服务至关重要.
科学领域:
- 神经学 神经学
- 医疗保健服务研究 医疗服务研究
- 患者报告的结果
背景情况:
- 患者报告结果 (PRO) 在临床实践中越来越受欢迎.
- 这项研究批判性地评估了目前在欧洲国家管理中PRO的使用和看法.
研究的目的:
- 评估关于在病护理中实施PRO的最新情况和信念.
- 了解PRO对决策和国家卫生当局利益的影响.
主要方法:
- 与欧洲专家进行结构化采访,包括神经病学家,卫生经济学家和流行病学家.
- 询问的重点是个人经验,国家层面的影响以及卫生当局与PRO的接触.
主要成果:
- PRO是在参与国家的临床试验/项目中收集的.
- 在日常实践中常规的PRO采集有所不同,从奥地利和瑞典到其他地方的医生自由裁量权.
- 专家们一致认为,PRO对临床结果,资源使用和患者满意度有积极的影响.
结论:
- 在整个欧洲,人们对中PRO的态度存在显著差异.
- 需要一个协调的战略来标准化PRO测量,以提高患者和医疗服务的相关性.
更多相关视频
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
188
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
188
Arteries of the Lower Limbs
192
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
192
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
317
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
317
Guidelines for Writing Outcome
2.8K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
2.8K
Electroconvulsive Therapy
44
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
44
Antiepileptic Drugs: GABAergic Pathway Potentiators
419
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
419


